IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Review On Trends In Liquid Chromatography For Pharmaceuticals

[1] Mr. Prashant R. Nalawade, [2] Ms. Pratibha M. Makar, [3] Dr. Vijaykumar Kale, [4] Dr. Mahesh Thakare , [5] Mr. Vaibhav Narwade

Student, Assistant professor, Professor, Associate professor, Assistant professor

Bachelor of pharmacy, (Kasturi Shikshan Sanstha's College of Pharmacy Shikrapur, Pune)

***Abstract*:**

Liquid Chromatography (LC) remains the cornerstone of pharmaceutical analysis, but the demands for higher throughput, complex molecule analysis, and sustainability have driven a profound technological transformation. This review comprehensively examines the critical trends defining modern LC. The shift to Ultra-High Performance Liquid Chromatography (UHPLC) and core-shell technology has delivered superior speed and resolution by leveraging sub-2 µm particles. Concurrently, the coupling of LC with High-Resolution Mass Spectrometry (HRMS) has become indispensable for unknown impurity identification and the characterization of complex biopharmaceuticals via the Multi-Attribute Method (MAM). Methodological advancements are anchored by Quality by Design (QbD), utilizing statistical tools like Design of Experiments (DoE) to create robust, regulatory-compliant analytical methods. Furthermore, the commitment to Green Analytical Chemistry is realized through the adoption of techniques like Supercritical Fluid Chromatography (SFC), significantly reducing organic solvent consumption. Future trends point towards greater automation, integration of Artificial Intelligence, and continued miniaturization to meet the challenges of an increasingly complex drug pipeline. The development of these chromatographic techniques and their vital significance in pharmaceutical process optimization, product quality assurance, and regulatory compliance throughout the drug development lifecycle will be covered in this study. This review provides the state of the art of green analytical methodologies for environmental analysis of pharmaceutically active compounds in the aquatic environment with special emphasis on strategies for greening liquid chromatography (LC).

Keywords: LC-MS, UHPLC, Green Chromatography, QbD, SFC, Chiral Separation, HRMS.

I . Introduction:

Liquid Chromatography (LC) stands as the gold standard analytical technique throughout the lifecycle of pharmaceutical products—from initial discovery and formulation development to quality control (QC) and stability testing. Its fundamental capability to separate, identify, and quantify individual components within complex matrices makes it indispensable for ensuring the efficacy, safety, and regulatory compliance of medicines. [1]

The pharmaceutical industry relies heavily on LC for several crucial applications:

• **Active Pharmaceutical Ingredient (API) Purity:** Accurate determination of the concentration of the API.

• **Impurity Profiling:** Identifying and quantifying minute levels of related substances, degradation products, and process impurities (e.g., genotoxic impurities, solvents).

• **Stability Studies:** Monitoring drug substance and drug product degradation over time, a mandatory requirement under International Council for Harmonisation (ICH) guidelines.

• **Pharmacokinetic Studies:** Measuring drug concentration in biological fluids.

The historical foundation of LC, primarily built on conventional High-Performance Liquid Chromatography (HPLC), utilized column particles generally greater than 5 µm and operated at moderate pressures. While robust and reliable, the increasing complexity of modern therapeutics and the global demand for faster drug development necessitated a revolutionary leap in chromatographic performance. [1]

The Evolution and Drivers of Change:

The drive for innovation in LC is rooted in both scientific progress and regulatory pressure. The transition from conventional HPLC to modern, high-efficiency techniques is motivated by three principal factors:

A. Managing Increased Molecular Complexity The pharmaceutical pipeline has shifted to include complex drug modalities such as biopharmaceuticals (e.g., monoclonal antibodies, cell and gene therapies) and synthetic molecules like oligonucleotides and antibody-drug conjugates (ADCs). Analysing these large, heterogeneous molecules requires methods with vastly improved peak capacity and orthogonality to resolve highly similar structural variants or degradation products. This demand fuelled the development of systems that could exploit smaller particles and higher pressures, leading directly to the adoption of Ultra-High-Performance Liquid Chromatography (UHPLC). [4]

B. Regulatory Demand for Trace Analysis and Quality by Design (QbD) Regulatory bodies worldwide have continually tightened limits on impurities, particularly those with high toxicological risk (e.g., N-nitrosamines). Quantifying these species often requires limits of quantification (LOQs) down to the low parts per billion (ppb) range. This necessitates the integration of LC with highly sensitive and selective detectors, particularly High-Resolution Mass Spectrometry (HRMS). Furthermore, the push towards Quality by Design (QbD) (ICH Q8, Q9, Q10) requires robust, well-understood analytical methods, transitioning method development from an empirical process to a systematic, risk-based science. [9,14]

C. The Imperative for Speed, Throughput, and Sustainability The high-volume nature of pharmaceutical QC laboratories demands significantly reduced run times. Moreover, there is a global movement toward Green Analytical Chemistry (GAC), emphasizing the reduction, replacement, and recycling of solvents. Modern LC techniques address these needs by:

• **Reducing Run Times:** UHPLC can cut analysis time by up to 10-fold.

• **Reducing Solvent Waste:** Smaller column dimensions and faster flows dramatically reduce mobile phase consumption (up to 90% reduction).

• **Replacing Solvents:** The rise of Supercritical Fluid Chromatography (SFC) offers a greener alternative by utilizing supercritical carbon dioxide ($scCO_2$). [4,10,11]

II. Modern Advancements in LC Hardware:

The demand for higher throughput, better resolution, and reduced solvent consumption has driven significant innovation in the fundamental components of Liquid Chromatography (LC) systems, particularly in pumping technology and column media.

2.1. Ultra-High-Performance Liquid Chromatography (UHPLC):

The single most significant hardware evolution in the last two decades is the widespread adoption of Ultra-High-Performance Liquid Chromatography (UHPLC). This technology revolutionizes separation science by fundamentally altering the parameters of the chromatographic system.

A. Principle and Advantages UHPLC systems are engineered to utilize chromatographic columns packed with particles less than 2 µm in diameter, which, according to the Van Deemter equation, significantly

increases column efficiency (N). The core principle is that smaller particles provide higher efficiency and resolution (Rs) at faster flow rates compared to traditional HPLC columns (>5 µm particles).

However, utilizing these small particles generates extremely high backpressures, often exceeding 1000 bar (or 100 MPa). Therefore, UHPLC requires robust instrument design, including:

- High-pressure capable pumps (often operating up to 1500 bar).
- Low-volume injector systems and detector flow cells to minimize extra-column band broadening.
- System components with reduced dead volume.
- The primary benefits realized by pharmaceutical laboratories are:
- Speed: Run times can be reduced from 30–60 minutes (HPLC) to under 5 minutes, dramatically increasing sample throughput.
- Resolution**:** The increased efficiency allows for better separation of closely eluting peaks, which is critical for resolving complex impurity profiles.
- Sensitivity: Sharper, narrower peaks lead to an increase in peak height, thus improving the sensitivity of the analysis.

Theoretical Foundation: The Van Deemter Curve The relationship between column efficiency and mobile phase velocity is described by the Van Deemter equation:

$$H=A+uB+C\cdot u$$

where H is the plate height, u is the linear velocity, A represents eddy diffusion, B represents longitudinal diffusion, and C represents mass transfer resistance.

For conventional HPLC particles, the C term, related to mass transfer, dominates at higher flow rates, causing a rapid increase in plate height (loss of efficiency). In UHPLC, the very small particle size significantly reduces the C term. This allows the optimum linear velocity to be higher, enabling analysts to run the method much faster without losing efficiency. This effect is visually represented by the shift and flattening of the Van Deemter curve. [3,4]



Figure 1: Schematic Representation of High-Performance Liquid Chromatography [17]

2.2. Advanced Column and Separation Technology: Beyond the move to sub-2 µm particles, innovation in stationary phase architecture is enhancing separation power and selectivity.

A. Core-Shell (Fused-Core) Technology Core-shell particles represent a compromise between the high efficiency of small particles and the low backpressure of larger particles. These particles feature a non-porous solid silica core surrounded by a thin layer of porous material where the separation takes place.

• **Mechanism:** The short diffusion path through the thin porous shell dramatically reduces the mass transfer term (C term in the Van Deemter equation), yielding efficiencies comparable to, or sometimes exceeding, UHPLC columns, but at significantly lower backpressures.

• **Advantage:** This allows older, conventional HPLC instruments (rated for 400 bar or 600 bar) to achieve near-UHPLC performance, effectively extending the lifespan of existing laboratory hardware while realizing efficiency benefits.

B. Column Miniaturization: Micro-Flow and Nano-LC There is a growing trend toward using columns with smaller internal diameters (IDs) (e.g., 2.1 mm to 1.0 mm to 0.3 mm) for high-sensitivity applications, particularly when coupled with Mass Spectrometry (MS).

• **Benefit:** Reducing the column ID drastically reduces the required flow rate, often translating to a 90% or greater reduction in mobile phase consumption.

• **Application:** Micro-flow and nano-LC are essential for analysis where the sample volume is scarce (e.g., biological samples, drug metabolites) and where increased detector sensitivity (due to reduced dilution) is paramount, especially for LC-MS applications. This aligns directly with the principles of Green Analytical Chemistry.

C. Novel Stationary Phases Specialized phases are required to handle the diverse chemical nature of modern pharmaceuticals:

• **Polar Phases:** Hydrophilic Interaction Liquid Chromatography (HILIC) phases are essential for retaining and separating highly polar, water-soluble drugs and their metabolites, which are poorly retained by traditional reversed-phase LC (RPLC).

• **Bioseparations:** Dedicated phases for large molecules, including non-porous or wide-pore silica materials, are used in Size-Exclusion Chromatography (SEC) for aggregate analysis and Ion-Exchange Chromatography (IEX) for charge-variant separations of monoclonal antibodies. [6,13]

2.3. Multidimensional and Unified Chromatography:

To address the highest level of sample complexity (e.g., impurity profiling in new drug substances, complex biopharma digests), Multidimensional LC (MD-LC), often referred to as LC×LC, is becoming indispensable.

• **2D-LC (LC×LC):** This technique uses two columns with orthogonal separation mechanisms (e.g., RPLC in the first dimension and HILIC in the second). By coupling them, the peak capacity of the system is the product of the individual column capacities, resulting in a dramatic increase in resolution for highly complex mixtures that would co-elute in a single dimension.

• **Unified Chromatography (UC):** This term often refers to systems capable of seamlessly switching between LC and Supercritical Fluid Chromatography (SFC) modes using the same core hardware. This versatility allows a single platform to handle both traditional reverse-phase analysis and highly efficient chiral/green separations. [5]

III. The Synergy of LC-Mass Spectrometry (LC-MS):

While advancements in LC hardware provide superior separation power, modern pharmaceutical analysis relies on selective and sensitive detection to identify and quantify trace components. This has made the coupling of Liquid Chromatography with Mass Spectrometry (LC-MS) the dominant analytical platform in research, development, and quality control.

3.1. LC-MS: The Standard for Qualitative Analysis:

The primary strength of LC-MS lies in its ability to provide molecular weight and, through fragmentation, structural information for eluting compounds. This is a crucial advantage over traditional detectors like UV/PDA, which only provide spectroscopic characteristics.

A. Ionization Sources and Challenges The core challenge in hyphenating LC and MS is the efficient transfer of compounds from the liquid phase to the gas phase for mass analysis.

• **Electrospray Ionization (ESI):** The most common technique, particularly effective for polar and high-molecular-weight compounds (e.g., peptides, proteins). ESI uses a high voltage to create charged droplets that evaporate, leaving protonated or deprotonated analyte ions.

• **Atmospheric Pressure Chemical Ionization (APCI):** Often preferred for less polar or non-polar compounds, APCI uses a corona discharge to ionize molecules.

A key issue to manage is the matrix effect, where co-eluting, non-target sample components (the matrix) interfere with the ionization efficiency of the target analyte, leading to signal suppression or enhancement. Method optimization, including improved chromatographic separation (UHPLC/2D-LC) and matrix removal steps, is essential to mitigate this. [8]

3.2. High-Resolution Mass Spectrometry (HRMS) for Impurity Profiling :

The demand for unambiguous identification of unknown impurities has cemented High-Resolution Mass Spectrometry (HRMS) as an indispensable tool. HRMS systems can measure the mass-to-charge ratio (m/z) with extremely high accuracy (often below 5 parts per million, ppm mass error), allowing the precise determination of the elemental composition of an analyte.

A. HRMS Techniques :

• Time-of-Flight (TOF) and Quadrupole-Time-of-Flight (Q-TOF): Offer rapid acquisition and high mass accuracy, making them excellent for screening and identification of complex mixtures.

• **Orbitrap Mass Analyzers:** Known for exceptional mass resolving power and accuracy, these systems are critical for elucidating the structure of highly similar isomers and trace-level degradation products.

B. Pivotal Application: Unknown Impurity Identification In pharmaceutical development, regulators require that all impurities above a certain threshold (e.g., 0.1% or 0.5%, depending on dose) must be identified. The workflow involves:

1. Accurate Mass Measurement: Determining the exact mass of the unknown peak.

2. Formula Generation: Using the accurate mass to calculate the possible elemental composition (e.g.,Cx Hy Nz Oa).

3. Fragmentation (MS/MS): Utilizing tandem mass spectrometry (MS) to break down the unknown molecule into characteristic fragments. The resulting fragmentation pattern, when matched with the formula, allows for structural confirmation.

C. Case Study: Genotoxic Impurities (GTIs) and N-Nitrosamines The stringent control of highly potent compounds like Genotoxic Impurities (GTIs) and, recently, N-Nitrosamines (detected in common drug classes like Sartans and Ranitidine), requires analytical sensitivity down to the low ppb or ppt range. LC-HRMS, coupled with UHPLC to manage matrix load, is the primary technique meeting this extreme sensitivity and specificity requirement, often replacing less specific detectors. [9]

3.3. LC for Biopharmaceutical Characterization:

LC-MS is not just for small molecules; it is foundational for the characterization of biopharmaceuticals (large molecules), particularly monoclonal antibodies (mAb) and peptides.

A. Multi-Attribute Method (MAM): The trend in Biopharma QC is moving toward the Multi-Attribute Method (MAM). This LC-HRMS-based strategy monitors multiple Critical Quality Attributes (CQAs)—such as glycosylation, oxidation, deamidation, and aggregation—within a single, high-resolution run. MAM aims

to replace multiple traditional assays (e.g., IEX, SEC, peptide mapping) with a single, information-rich LC-MS method, thereby streamlining QC processes.

B. Specialized LC Modes for Large Molecules LC is used in orthogonal modes before MS analysis:

• **Peptide Mapping:** RPLC-MS is used after enzymatic digestion of a protein (e.g., a mAb) to verify the sequence and monitor post-translational modifications (PTMs).

• **Intact Mass Analysis:** SEC-MS or RPLC-MS is used to determine the mass of the entire protein, providing rapid confirmation of the primary structure.

• **Charge Heterogeneity:** IEX-MS is used to analyze charge variants caused by modifications like C-terminal lysine truncation. [7]

IV. Green and Sustainable Liquid Chromatography :

The environmental impact of laboratory operations, particularly the use and disposal of large volumes of organic solvents, has driven the pharmaceutical industry to embrace the principles of Green Analytical Chemistry (GAC). LC, as a major consumer of solvents, is central to this sustainability movement.

4.1. Principles of Green Analytical Chemistry (GAC) :

GAC is guided by a set of principles aimed at minimizing the generation of hazardous waste and reducing energy consumption in analytical procedures. The overarching goal for LC is to adhere to the 3Rs principle:

1. Reduce: Decrease the consumption of organic solvents.

2. Replace: Substitute toxic or hazardous solvents (e.g., hexane, dichloromethane) with safer, less environmentally damaging alternatives (e.g., ethanol, water, supercritical $scCO_2$).

3. Recycle: Implement effective strategies for mobile phase recycling and regeneration.

To quantify the environmental footprint of an LC method, metrics such as the Analytical Method Volume Intensity (AMVI)—which measures the volume of solvent used per sample—are increasingly employed. This quantitative approach allows laboratories to compare methods and prioritize the adoption of greener alternatives. [10,12]

4.2. Supercritical Fluid Chromatography (SFC) :

The most significant "green" alternative to conventional liquid separation is **Supercritical Fluid Chromatography (SFC).**

A. Green Mobile Phase SFC utilizes a mobile phase composed primarily of supercritical carbon dioxide ($scCO_2$), which possesses unique physicochemical properties:

• **Viscosity:** $scCO_2$ has a viscosity similar to a gas, allowing for very high flow rates and rapid separations.

• **Solvency:** It has solvating power comparable to a liquid, making it an effective solvent for many organic compounds.

The primary modifier in SFC is typically a polar organic solvent (e.g., methanol, ethanol), but the overall volume of organic solvent consumed is drastically reduced because $scCO_2$ makes up the bulk of the mobile phase (often >95%). Furthermore, $scCO_2$ can be easily recycled or vented safely, leaving behind minimal liquid waste. [11]

B. Key Application: Chiral Separations SFC has become the preferred technique for chiral separation in the pharmaceutical industry. Many chiral stationary phases (CSPs) exhibit enhanced selectivity and efficiency when used with $scCO_2$ mobile phases compared to conventional LC. The speed and high loading capacity of SFC systems make them ideal for both analytical-scale and large-scale preparative chiral chromatography, which is essential for producing single-enantiomer drugs, as required by regulatory bodies. [11]

4.3. LC System Miniaturization and Replacement Solvents:

Beyond SFC, the trend toward miniaturization inherent in UHPLC provides direct environmental benefits.

• **Micro-Flow and Capillary LC:** As discussed in Section III, using 1.0 mm or smaller inner diameter columns, coupled with flow rates in the µL/min range, reduces mobile phase consumption by orders of magnitude compared to standard 4.6 mm columns. This represents a simple yet powerful strategy for achieving solvent reduction.

• **Aqueous Mobile Phases:** Research continues into replacing hazardous organic solvents with less toxic alternatives. [10]

V. LC in Specialized Pharmaceutical Applications:

Modern Liquid Chromatography systems, especially when coupled with advanced detection, are essential tools for tackling specific, high-stakes analytical challenges in the pharmaceutical industry.

5.1. Separation of Biopharmaceuticals (Large Molecules):

• **Size-Exclusion Chromatography (SEC):** Used to separate proteins based on their hydrodynamic radius (size). Critical for detecting and quantifying aggregates and fragments of the therapeutic protein.

• **Ion-Exchange Chromatography (IEX):** Separates proteins based on their charge heterogeneity, which arises from chemical modifications (e.g., deamidation, oxidation).

• **Hydrophobic Interaction Chromatography (HIC**): Used for Antibody-Drug Conjugates (ADCs) to determine the Drug-to-Antibody Ratio (DAR) distribution.

•**Bioanalysis of Oligonucleotides:** Analysed using specialized techniques like Ion-Pair Reversed-Phase LC (IP-RPLC) and Hydrophilic Interaction LC (HILIC). [13]

5.2. Chiral Separations (Enantiomeric Purity):

• **Regulatory Imperative:** Regulatory bodies require precise determination of the enantiomeric purity of chiral drugs.

• **Chiral Stationary Phases (CSPs):** Primary LC approach involves using CSPs (e.g., polysaccharide derivatives) that selectively interact with one enantiomer.

• **Integration with SFC**: Supercritical Fluid Chromatography (SFC) is the technique of choice for both analytical and preparative chiral separations due to its speed, selectivity, and green nature.

•**Chiral LC-MS/MS:** Provides exceptional specificity and sensitivity for quantifying trace levels of the unwanted enantiomer (chiral impurity) in complex biological matrices. [11]

5.3. Impurity Profiling and Forced Degradation Studies:

• **Forced Degradation Studies (FDS):** LC is used to separate the parent drug from all degradation products created under harsh conditions (heat, light, hydrolysis).

• **Stability-Indicating Methods (SIMs):** The LC method must demonstrate its ability to resolve the API peak from all potential impurities.

• **LC-HRMS for Elucidation:** High-Resolution Mass Spectrometry (HRMS) is essential for identifying the structure of unknown degradants and process-related impurities, which is vital for mitigating genotoxic or toxic risks.

• **2D-LC for Complex Samples:** Used to provide additional separation power when impurities are structurally very similar to the API, ensuring trace impurities co-eluting with the main peak are fully resolved. [9,15]

VI. Quality by Design (QbD) in LC Method Development:

The shift from empirical method development to a structured, scientific, and risk-based approach—Quality by Design (QbD)—ensures that analytical methods are robust and "fit for purpose" throughout their lifecycle.

6.1. The QbD Framework:

The process begins with defining the Analytical Target Profile (ATP), which explicitly states the required performance criteria (e.g., Rs, accuracy). A formal Risk Assessment (e.g., FMEA) then links Critical Method Parameters (CMPs)(e.g., mobile phase pH, column temperature) to the Critical Quality Attributes (CQAs) (e.g., resolution, peak tailing). [14]

6.2. Method Development and Control Strategy: The core of the QbD process uses Design of Experiments (DoE) to systematically explore the effects and interactions of CMPs on CQAs.

• **DoE:** Replaces the inefficient One-Factor-at-a-Time (OFAT) approach to build a mathematical model that predicts performance.

• **Design Space:** The validated output is the Analytical Design Space, which is the multi-dimensional range of CMPs proven to yield results meeting the ATP. Working within this space is not considered a method change, offering flexibility for QC labs.

• **Control Strategy:** This outlines the defined ranges for all CMPs (the Method Operability Range or MOR) and specifies the necessary System Suitability Tests (SSTs). [14,16]

6.3. Automation and Data Handling:

The complexity of QbD is managed by integrating Automated Method Development (AMD) software with Chromatographic Data Systems (CDS). The final methods are managed within Laboratory Information Management Systems (LIMS), with future trends focusing on integration with Artificial Intelligence (AI) for continuous method monitoring and predictive maintenance. [16]

VII. Conclusion:

A paradigm shift toward high-efficiency, high-selectivity separation platforms that can resolve progressively complex pharmaceutical matrices is demonstrated by developments in liquid chromatography. Peak capacity, trace-level detection, and structural elucidation have been greatly improved by innovations including sub-2 µm UHPLC systems, core-shell stationary phases, multidimensional LC, and LC–HRMS integration. At the same time, automated method creation, design-space modelling, and sophisticated data-handling workflows have become more popular due to regulatory demands for strong, QbD-driven analytical control strategies. Sustainability-driven technologies, such as micro-flow LC and SFC, further establish chromatography as an environmentally conscious and analytically potent method. All of these developments support LC as a vital, forward-thinking platform for thorough pharmacological analysis.

VIII. Acknowledgement:

Would like to thank our guide Miss. Pratibha M. Makar who took his valuable time to guide us throughout the process.

IX. References:

[1] Skoog, D. A., Holler, F. J., & Crouch, S. R. (Most Recent Edition). Principles of Instrumental Analysis. Cengage Learning.

[2] Jandera, P. (2020). Recent advances in contemporary liquid chromatography: Principles and practice. Journal of Chromatography A, 1625, 461327.

[3] Gritti, F. (2018). The fundamentals of high-performance liquid chromatography and ultra-high-pressure liquid chromatography: Why they are the same and why they are not. Separation Science plus, 1(4), 1800007.

[4] Fountain, K. J., & Gilar, M. (2020). Ultrahigh-performance liquid chromatography: 15 years of rapid progress. TrAC Trends in Analytical Chemistry, 124, 115793.

[5] D'Orazio, G. (2016). Recent advances in two-dimensional liquid chromatography (2D-LC). Analytical and Bioanalytical Chemistry, 408(17), 4561-4573.

[6] Fekete, S., Schappler, J., & Rudaz, S. (2014). Core-shell columns in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis, 101, 169-175.

[7] Gross, M. L. (2017). Mass spectrometry: A major contributor to pharmaceutical development. Mass Spectrometry Reviews, 36(1), 1-22.

[8] Hewlett, J. S., & Russell, J. E. (2020). LC–MS for pharmaceutical quality control: A systematic review. Journal of Pharmaceutical and Biomedical Analysis, 186, 113303.

[9] Fornells, E., et al. (2020). Analytical strategy for the determination of N-nitrosamine impurities in pharmaceuticals using LC-HRMS. Journal of Chromatography A, 1629, 461522.

[10] Tuzimski, T. (2019). Green analytical chemistry approaches in liquid chromatography. TrAC Trends in Analytical Chemistry, 120, 115655.

[11] Miller, J. M., & Lynam, D. P. (2018). Supercritical fluid chromatography in the pharmaceutical industry: A review of the past two decades. Chromatographia, 81(1), 3-18.

[12] Guzman, A., et al. (2021). The Green Analytical Chemistry (GAC) metric: A tool for evaluating and comparing liquid chromatographic methods. Talanta, 223, 121666.

[13] Fekete, S., Veuthey, J. L., & Guillarme, D. (2021). Advances in liquid chromatography for the analysis of therapeutic proteins. Analytica Chimica Acta, 1146, 337920.

[14] Novak, I., & Urban, M. (2019). Method development by Quality-by-Design in pharmaceutical liquid chromatography: Challenges and future perspectives. Journal of Chromatography A, 1599, 113-125.

[15] ICH Harmonised Tripartite Guideline Q2(R2): Validation of Analytical Procedures. (Current regulatory guideline.)

[16] ICH Harmonised Tripartite Guideline Q14: Analytical Procedure Development. (Current regulatory guideline on QbD for analytical methods.)

[17] Sneha Lakshmi, RP. A review on chromatography with high performance liquid chromatography (HPLC) and its functions. Rev.: J. Pharm. Anal., 2015, 4(1), 1-15